> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Catalent Biologics FDA-483 Posted
- URL: https://www.fdaweb.com/catalent-biologics-fda-483-posted/
- Published: 2022-04-04T12:00:00.000Z
- Updated: 2026-09-14T17:39:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151516

FDA has posted a one-item Form FDA-483 for Catalent Biologics (Bloomington, IN) from a 2020 inspection at the manufacturing site. The inspection report cited Catalent over its procedures to prevent microbiological contamination for sterile drug products. FDA said the firm did not always follow good aseptic techniques at the plant. Additionally, FDA said operators at the plant were observed entering an area to perform interventions without proper sanitizing. To view the FDA-483, click [here](https://www.fda.gov/media/157407/download?ref=fdaweb.com).